Inozyme Pharma, Inc is a Boston-based biopharmaceutical company dedicated to developing breakthrough solutions for rare diseases characterized by pathologic mineralization and intimal proliferation. With a focus on restoring health and hope to patients and their families, Inozyme brings together leading talent to create life-saving therapies driven by empathy, compassion, and tireless innovation.
Through their cutting-edge science and collaboration with patients, families, and healthcare providers, Inozyme is developing potential first-in-class enzyme therapies to address genetic and non-genetic diseases involving low levels of inorganic pyrophosphate (PPi) and adenosine. Their novel enzyme therapy, INZ-701, aims to increase PPi and adenosine levels, mimicking the function of the membrane-bound ENPP1 protein. With a commitment to clinical trials and patient participation, Inozyme is at the forefront of delivering hope and rare solutions for patients with rare diseases.
Generated from the website